Results 31 to 40 of about 178,280 (162)
New acute onset of ocular myasthenia gravis after COVID-19 vaccine: A case report
Reports have shown the association of coronavirus disease 2019 (COVID-19) with several neuromuscular disorders. Myasthenia gravis (MG) is an autoimmune disease in which antibodies bind to acetyl choline receptors in the postsynaptic membrane at the ...
Himani T. Chaturvedi +3 more
doaj +1 more source
Antibodies to acetylcholine receptor in parous women with myasthenia: evidence for immunization by fetal antigen [PDF]
The weakness in myasthenia gravis (MG) is mediated by autoantibodies against adult muscle acetylcholine receptors (AChR) at the neuromuscular junction; most of these antibodies also bind to fetal AChR, which is present in the thymus.
Wilcox, Nick +13 more
core +1 more source
Off-center presentation of ocular myasthenia
Myasthenia gravis is an autoimmune condition with varied presentations. In this, we report a 70 years old diabetic male who came complaining of diplopia.
Mary A Stephen +2 more
doaj +1 more source
Fatigue and Muscle Atrophy in a Mouse Model of Myasthenia Gravis Is Paralleled by Loss of Sarcolemmal nNOS [PDF]
Myasthenia Gravis (MG) patients suffer from chronic fatigue of skeletal muscles, even after initiation of proper immunosuppressive medication. Since the localization of neuronal nitric oxide synthase (nNOS) at the muscle membrane is important for ...
Meinen, Sarina +7 more
core +2 more sources
Diplopia in a patient presenting with “blurred vision”: a case report
Background Myasthenia gravis is an autoimmune condition affecting the neuromuscular junction and causing muscle weakness along with fatigue (myasthenia).
Anil Harrison +3 more
doaj +1 more source
Quality of life in purely ocular myasthenia in Japan [PDF]
Background: Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, treatment guidelines were recently issued by the European Federation of Neurological Societies/European Neurological Society (EFNS/ENS).
Murai, Hiroyuki +23 more
core +2 more sources
Consistent improvement with eculizumab across muscle groups in myasthenia gravis
Objective To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale ...
Renato Mantegazza +4 more
doaj +1 more source
SARS-CoV-2 in pre-existing autoimmune myasthenia gravis: An institutional experience [PDF]
The impact of SARS-CoV-2 on pre-existing chronic neuromuscular junction disorders like myasthenia gravis (MG) is not known. We report three patients with pre-existing acetylcholine receptor autoantibody-positive myasthenia gravis who were infected with ...
Nitisha Goyal +3 more
doaj +1 more source
Background Ocular myasthenia gravis and Graves’ ophthalmopathy are autoimmune diseases that are mediated by membrane receptors and share many identical clinical processes.
Jingqun Tang, Chao Qin
doaj +1 more source
Myasthenia gravis is an autoimmune neuromuscular disease characterized by pathologically rapid fatigue of striated muscles [1]. The main symptom of myasthenia gravis is the presence of pathological muscle weakness with involvement of the ocular, bulbar ...
N. M. Kruglyakov +8 more
doaj +1 more source

